Propanc Biopharma Common Stock Analysis

Propanc Pink Sheet Analysis Notes

The company recorded a loss per share of 0.09. Propanc Biopharma Common last dividend was issued on the 19th of November 2020. The entity had 1:1000 split on the 19th of November 2020. Propanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia. Propanc Biopharma operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 1 people.The quote for Propanc Biopharma Common is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. To find out more about Propanc Biopharma Common contact James Nathanielsz at 61 3 9882 0780 or learn more at https://www.propanc.com.

Propanc Biopharma Common Investment Alerts

Propanc Market Capitalization

The company currently falls under 'Nano-Cap' category with a current market capitalization of 705.56 K. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Propanc Biopharma,'s market, we take the total number of its shares issued and multiply it by Propanc Biopharma,'s current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Technical Drivers

As of the 9th of February, Propanc Biopharma, holds the Risk Adjusted Performance of (0.23), coefficient of variation of (331.65), and Variance of 61.1. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Propanc Biopharma,, as well as the relationship between them.

Propanc Biopharma Common Price Movement Analysis

Propanc Biopharma, Outstanding Bonds

Propanc Biopharma, Predictive Daily Indicators

Propanc Biopharma, Forecast Models

Propanc Biopharma,'s time-series forecasting models are one of many Propanc Biopharma,'s pink sheet analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Propanc Biopharma,'s historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Propanc Biopharma Common Debt to Cash Allocation

Propanc Biopharma Common currently holds 1.1 M in liabilities. Debt can assist Propanc Biopharma, until it has trouble settling it off, either with new capital or with free cash flow. So, Propanc Biopharma,'s shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Propanc Biopharma Common sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Propanc to invest in growth at high rates of return. When we think about Propanc Biopharma,'s use of debt, we should always consider it together with cash and equity.

Propanc Biopharma, Assets Financed by Debt

Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Propanc Biopharma,'s operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Propanc Biopharma,, which in turn will lower the firm's financial flexibility.

Propanc Biopharma, Corporate Bonds Issued

Pink Sheet analysis is the technique used by a trader or investor to examine and evaluate how Propanc Biopharma, prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Propanc shares will generate the highest return on investment. We also built our pink sheet analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Pink Sheet such as Propanc Biopharma,. By using and applying Propanc Pink Sheet analysis, traders can create a robust methodology for identifying Propanc entry and exit points for their positions.

When running Propanc Biopharma,'s price analysis, check to measure Propanc Biopharma,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Propanc Biopharma, is operating at the current time. Most of Propanc Biopharma,'s value examination focuses on studying past and present price action to predict the probability of Propanc Biopharma,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Propanc Biopharma,'s price. Additionally, you may evaluate how the addition of Propanc Biopharma, to your portfolios can decrease your overall portfolio volatility.